MRSH at a glance
Marsh McLennan (MRSH, SEC CIK 62709) filed its latest 10-K annual report on February 9, 2026, a 10-Q quarterly report on July 21, 2026, an 8-K current report on July 21, 2026 and Form 4 insider filings as recently as September 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Marsh McLennan (MRSH) reported revenue of $27.0 billion (up 10.3% from FY2024) and net income of $4.2 billion. Diluted EPS was $8.43.
- As of June 30, 2026, 44 institutional investment managers tracked by SignalX reported holding Marsh McLennan (MRSH) shares worth $29.5 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Doyle John Q on September 2, 2026 of 16,656 shares at $188.51 per share.
- In the last 90 days, MRSH insiders reported 0 open-market purchases ($0) and 6 open-market sales ($8.2M) on Form 4, a net sale of $8.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $27.0B
- +10.3% vs prior year
- Insiders · 90 days
- 0 buys · 6 sells
- Net −$8.2M
- 13F holders
- 44 funds
- $29.5B · −3 vs prior quarter
- Latest 8-K
- Jul 21, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Risk Factors
- Regulatory risk: Compliance costs and penalties under GDPR, CCPA, emerging EU AI Act impacting financial condition and reputation
- Geopolitical threat: Exposure to conflict zones including Ukraine war, Middle East tensions, and Latin America impacting economic markets and client demand
- Operational vulnerability: Reliance on third-party vendors and introducers may cause harm if these parties fail or act improperly
- Market disruption: Competitive pressures including disintermediation and evolving landscape threatening growth in Risk and Insurance Services
- Financial risk: Significant uninsured exposures from errors and omissions and breach of fiduciary duty claims with potential for material losses
Management Discussion & Analysis
- Revenue $27.0B, up 10% YoY ($2.5B increase), underlying growth 4%; Risk & Insurance Services +12%, Consulting +7%
- Operating income $6.2B, up 7% YoY; Risk & Insurance margin 26.8% down from 28.4%, Consulting margin flat at 19.4%
- Best segment: Risk & Insurance Services revenue $17.3B (+12%), operating income $4.6B; Worst: Corporate expenses $309M (-3%), net loss segment
- Cash flow: repaid $500M senior notes; share repurchases $2.0B (10.1M shares); dividends paid $1.7B; $857M spent on 20 acquisitions
- Outlook/risks: macro/geopolitical conflicts, trade policies, slower GDP, FX volatility, inflation, insurance premium rate changes could impact future results
Business Overview
- Core business model focused on risk management and consulting services (implied from company identity, no new business model details given)
- No new products, services, or segments introduced or emphasized in the 2026 filing text provided
- Emphasis on updated insider trading policies and compliance protocols with detailed Trading Securities Policy enhancements
- Referenced policies filed as Exhibits 19.1 and 19.2 to the 10-K, reflecting formalized governance and compliance documentation
- Heavy reliance on cross-references to 2026 Proxy Statement for compensation, stock ownership, and governance information
AI summary of the MRSH 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $7.404B, up 6% YoY from $6.974B; underlying growth 5%
- Operating margin 25.6% vs 26.2% YoY, with operating income $1.899B vs $1.829B
- Best performer Marsh Management Consulting: revenue $1.004B, up 15%; worst Guy Carpenter: $664M, down 2%
- Share repurchases $750M for 4.5M shares; five acquisitions totaled $181M
- Headwinds: declining insurance and reinsurance premium rates, lower interest rates, tariffs, geopolitical conflict and potential recession
Risk Factors
- Risk factors unchanged from 10-K; filing states potential material adverse effects if previously disclosed risks occur
- Share-repurchase authorization: $4.2 billion remaining at June 30, 2026
- Liquidity risk: amended and restated five-year credit agreement effective June 2, 2026
- Capital-allocation risk: 8.7 million shares repurchased for $1.5 billion during six months ended June 30, 2026
AI summary of the MRSH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026 released July 21, 2026
- Conference call scheduled for 8:30 a.m. Eastern time on July 21, 2026
Item EX-99.1: Item EX-99.1
- Q2 revenue $7.4B, up 6%; underlying growth 5%, indicating broad-based organic expansion
- Adjusted EPS $2.96, up 9%; GAAP EPS $2.63, with restructuring and litigation adjustments material
Item 1.02: Termination of a Material Definitive Agreement
- Termination of $3.5B unsecured five-year revolving credit facility dated October 11, 2023
- Replaced in connection with the New Facility, indicating refinancing of existing corporate liquidity
Item 1.01: Entry into a Material Definitive Agreement
- $4.25B multi-currency unsecured revolving facility, replacing and extending credit capacity through June 2031
- Term SOFR plus credit-rating-based margin, linking borrowing costs to Marsh & McLennan’s credit profile
Item 5.07: Submission of Matters to a Vote of Security Holders
- Annual meeting held May 21, 2026, with 90.34% shareholder participation
- All 13 director nominees elected to one-year terms, preserving board continuity
AI summaries of MRSH 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MRSH
Don't miss the next MRSH filing
- Alerts as it files. A push when MRSH files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MRSH, by share count.
- Ask anything. An AI agent that reads every MRSH filing and answers with sources.
MRSH alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Doyle John Q | Sell | Sep 2, 2026 | 16,656 | $188.51 |
| Brennan Katherine | Sell | Sep 2, 2026 | 1,197 | $187.90 |
| Doyle John Q | M | Sep 2, 2026 | 16,656 | - |
| Brennan Katherine | M | Sep 2, 2026 | 1,197 | $83.05 |
| Brennan Katherine | M | Sep 2, 2026 | 1,197 | - |
| Doyle John Q | M | Sep 2, 2026 | 16,656 | $73.19 |
| SCHAPIRO MORTON O | A | Aug 15, 2026 | 218.9 | $188.44 |
| Lute Jane H | A | Aug 15, 2026 | 144.27 | $188.44 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $24.5B | $27.0B |
| Operating Income | - | $5.8B | $6.2B |
| Net Income | $3.8B | $4.1B | $4.2B |
| Op. Margin | - | 23.8% | 23.1% |
| Net Margin | - | 16.6% | 15.4% |
| Balance Sheet | |||
| Total Assets | $48.0B | $56.5B | $58.7B |
| Equity | - | $13.5B | $15.3B |
| ROE | - | 30.0% | 27.2% |
| Per Share | |||
| EPS | $7.53 | $8.18 | $8.43 |
| Cash Flow | |||
| Operating CF | - | $4.3B | $5.3B |
| CapEx | $416.0M | $316.0M | $291.0M |
Source: XBRL data in Marsh McLennan (MRSH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate MRSH share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 44 | $29.54B |
| Q1 2026 | 47 | $32.17B |
| Q4 2025 | 48 | $34.70B |
| Q3 2025 | 50 | $39.32B |
| Q2 2025 | 46 | $42.51B |
| Q1 2025 | 47 | $35.42B |
| Q4 2024 | 38 | $25.68B |
| Q3 2024 | 34 | $11.34B |
- T. Rowe Price Group+2.46M (+22%)
- Goldman Sachs Group+555.7K (+15%)
- Invesco Ltd+421.0K (+11%)
- State Street Corp+330.7K (+1%)
- Vanguard Portfolio Management LLC+142.6K (+1%)
- FMR LLC (Fidelity)−3.23M (-32%)
- BlackRock−2.56M (-6%)
- Bank of America Corp−1.48M (-30%)
- JPMorgan Chase & Co−1.36M (-22%)
- AQR Capital Management−1.07M (-29%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 354 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MRSH filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 4 | Jul 31, 2026 | - | - | - |
| 4 | Jul 29, 2026 | - | - | - |
| 4 | Jul 24, 2026 | - | - | - |
| 8-K | Jul 21, 2026 | - | Analysis | - |
| 10-Q | Jul 21, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 8-K | May 22, 2026 | - | Analysis | |
| 4 | May 18, 2026 | - | - | |
| 4 | May 1, 2026 | - | - | - |
| 4 | May 1, 2026 | - | - | - |
| 4 | May 1, 2026 | - | - | - |
| 4 | May 1, 2026 | - | - | - |
| 4 | May 1, 2026 | - | - | - |
Related Financials companies
- AON · Aon plcInsurance Agents, Brokers & Service
- AJG · Arthur J. Gallagher & Co.Insurance Agents, Brokers & Service
- BWIN · Baldwin Insurance Group, Inc.Insurance Agents, Brokers & Service
- BRO · Brown & BrownInsurance Agents, Brokers & Service
- CRVL · CORVEL CORPInsurance Agents, Brokers & Service
- EHTH · eHealth, Inc.Insurance Agents, Brokers & Service
- ACT · Enact Holdings, Inc.Insurance Agents, Brokers & Service
- EQH · Equitable Holdings IncInsurance Agents, Brokers & Service
MRSH SEC filings: frequently asked questions
Are MRSH insiders buying or selling?
In the last 90 days, Marsh McLennan (MRSH) officers, directors and 10% owners reported no open-market purchases and 6 open-market sales worth $8.2 million by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold MRSH stock?
As of June 30, 2026, the largest Marsh McLennan (MRSH) holders among the 13F filers tracked by SignalX were BlackRock ($6.6 billion), Vanguard Capital Management LLC ($5.2 billion), State Street Corp ($3.7 billion), T. Rowe Price Group ($2.2 billion), Vanguard Portfolio Management LLC ($2.1 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MRSH's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Marsh McLennan (MRSH) reported revenue of $27.0 billion (up 10.3% from FY2024) and net income of $4.2 billion. Diluted EPS was $8.43. The figures come from the XBRL data in the 10-K.
What are the main risks in MRSH's latest 10-K?
In the 10-K filed February 9, 2026, Marsh McLennan (MRSH) flagged: Regulatory risk: Compliance costs and penalties under GDPR, CCPA, emerging EU AI Act impacting financial condition and reputation. Geopolitical threat: Exposure to conflict zones including Ukraine war, Middle East tensions, and Latin America impacting economic markets and client demand. (AI summary of the Risk Factors section.)
What did MRSH report in its latest 8-K?
Marsh McLennan (MRSH) filed an 8-K on July 21, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results for quarter ended June 30, 2026 released July 21, 2026.
What are the latest MRSH SEC filings?
Marsh McLennan (MRSH) filed its latest 10-K annual report on February 9, 2026, a 10-Q quarterly report on July 21, 2026, an 8-K current report on July 21, 2026 and a Form 4 insider filing on September 3, 2026.
What is MRSH's SEC CIK number?
Marsh McLennan (MRSH)'s SEC Central Index Key (CIK) is 62709. EDGAR lists every MRSH filing under that number.
Ask anything about MRSH
The research agent reads MRSH's filings, financials, insider trades and 13F holders, then answers with sources.